Atara Biotherapeutics Book Value 2011-2026 | ATRA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Atara Biotherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-38.5 M	-97.3 M	-99.2 M	127 M	280 M	462 M	291 M	339 M	178 M	254 M	315 M	103 M	-11 M	-3.73 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
462 M	-99.2 M	150 M

Quarterly Book Value Atara Biotherapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-36.6 M	-35 M	-55.1 M	-97.3 M	-90.5 M	-111 M	-98.3 M	-99.2 M	-50.8 M	7.45 M	65 M	127 M	187 M	257 M	224 M	280 M	310 M	332 M	399 M	462 M	462 M	462 M	462 M	291 M	291 M	291 M	291 M	339 M	339 M	339 M	339 M	178 M	178 M	178 M	178 M	254 M	254 M	254 M	254 M	315 M	315 M	315 M	315 M	103 M	103 M	103 M	103 M	50.1 M	50.1 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
462 M	-111 M	191 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Burford Capital Limited BUR	1.66 B	$ 4.73	0.42 %	$ 761 M	Britain
Cabaletta Bio CABA	112 M	$ 3.4	4.29 %	$ 342 M	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 333.39	-1.77 %	$ 43.7 B	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 3.17	3.93 %	$ 5.22 M	Israel
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.73	3.04 %	$ 8.97 B	Australia
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Esperion Therapeutics ESPR	-302 M	$ 2.17	5.85 %	$ 451 M	USA
Aligos Therapeutics ALGS	53.5 M	$ 7.42	-15.1 %	$ 73.3 M	USA
Forte Biosciences FBRX	61 M	$ 31.28	-3.52 %	$ 405 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Galapagos NV GLPG	3.24 B	$ 29.16	0.97 %	$ 2.69 B	Belgium
Genmab A/S GMAB	19.1 B	$ 29.3	0.83 %	$ 18.8 B	Danmark
GT Biopharma GTBP	6.78 M	$ 0.39	-0.26 %	$ 2.15 M	USA
Amphastar Pharmaceuticals AMPH	789 M	$ 21.68	1.4 %	$ 1.01 B	USA
Harmony Biosciences Holdings HRMY	870 M	$ 29.22	-0.24 %	$ 1.68 B	USA
BioNTech SE BNTX	19.2 B	$ 99.47	1.08 %	$ 27.2 B	Germany
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
ImmuCell Corporation ICCC	27.1 M	$ 7.6	-1.68 %	$ 68.6 M	USA
InflaRx N.V. IFRX	41.6 M	$ 1.21	6.14 %	$ 152 M	Germany
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	32.6 M	$ 1.55	-0.64 %	$ 399 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Incyte Corporation INCY	5.17 B	$ 97.1	-0.6 %	$ 19 B	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.24	2.17 %	$ 453 M	USA
Arcutis Biotherapeutics ARQT	189 M	$ 24.58	-2.03 %	$ 3.13 B	USA
Brainstorm Cell Therapeutics BCLI	-9.98 M	-	-2.5 %	$ 5.88 M	USA
Innate Pharma S.A. IPHA	267 M	$ 1.69	3.68 %	$ 235 M	France
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Autolus Therapeutics plc AUTL	178 M	$ 1.49	0.68 %	$ 397 M	Britain
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA